The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gong, J.
Right arrow Articles by Kufe, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gong, J.
Right arrow Articles by Kufe, D.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Ovarian Cancer
The Journal of Immunology, 2000, 165: 1705-1711.
Copyright © 2000 by The American Association of Immunologists

Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1

Jianlin Gong2,*, Najmosama Nikrui{dagger}, Dongshu Chen*, Shigeo Koido*, Zekui Wu*, Yasuhiro Tanaka*, Stephen Cannistra{ddagger}, David Avigan{ddagger} and Donald Kufe*

* Dana-Farber Cancer Institute, {dagger} Massachusetts General Hospital, and {ddagger} Beth Israel/Deaconess Medical Center, Harvard Medical School, Boston, MA 02115

Human ovarian carcinomas express the CA-125, HER2/neu, and MUC1 tumor-associated Ags as potential targets for the induction of active specific immunotherapy. In the present studies, human ovarian cancer cells were fused to human dendritic cells (DC) as an alternative strategy to induce immunity against known and unidentified tumor Ags. Fusions of ovarian cancer cells to autologous DC resulted in the formation of heterokaryons that express the CA-125 Ag and DC-derived costimulatory and adhesion molecules. Similar findings were obtained with ovarian cancer cells fused to allogeneic DC. The fusion cells were functional in stimulating the proliferation of autologous T cells. The results also demonstrate that fusions of ovarian cancer cells to autologous or allogeneic DC induce cytolytic T cell activity and lysis of autologous tumor cells by a MHC class I-restricted mechanism. These findings demonstrate that fusions of ovarian carcinoma cells and DC activate T cell responses against autologous tumor and that the fusions are functional when generated with either autologous or allogeneic DC.




This article has been cited by other articles:


Home page
J. Immunol.Home page
S. Koido, E. Hara, S. Homma, M. Mitsunaga, A. Takahara, E. Nagasaki, H. Kawahara, M. Watanabe, Y. Toyama, S. Yanagisawa, et al.
Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells
J. Immunol., October 1, 2007; 179(7): 4874 - 4883.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Koido, E. Hara, S. Homma, A. Torii, M. Mitsunaga, S. Yanagisawa, Y. Toyama, H. Kawahara, M. Watanabe, S. Yoshida, et al.
Streptococcal Preparation OK-432 Promotes Fusion Efficiency and Enhances Induction of Antigen-Specific CTL by Fusions of Dendritic Cells and Colorectal Cancer Cells
J. Immunol., January 1, 2007; 178(1): 613 - 622.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. I. Slukvin, M. A. Vodyanik, J. A. Thomson, M. E. Gumenyuk, and K.-D. Choi
Directed Differentiation of Human Embryonic Stem Cells into Functional Dendritic Cells through the Myeloid Pathway.
J. Immunol., March 1, 2006; 176(5): 2924 - 2932.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Koido, E. Hara, S. Homma, A. Torii, Y. Toyama, H. Kawahara, M. Watanabe, K. Yanaga, K. Fujise, H. Tajiri, et al.
Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancer-Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells
Clin. Cancer Res., November 1, 2005; 11(21): 7891 - 7900.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Tanaka, S. Koido, M. Ohana, C. Liu, and J. Gong
Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells
J. Immunol., February 1, 2005; 174(3): 1274 - 1280.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Suzuki, T. Fukuhara, M. Tanaka, A. Nakamura, K. Akiyama, T. Sakakibara, D. Koinuma, T. Kikuchi, R. Tazawa, M. Maemondo, et al.
Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells
Clin. Cancer Res., January 1, 2005; 11(1): 58 - 66.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Avigan
Dendritic Cell-Tumor Fusion Vaccines for Renal Cell Carcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6347S - 6352S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz, F. Ito, M. A. Davis, C. J. Mcginn, and A. E. Chang
Radiotherapy Potentiates the Therapeutic Efficacy of Intratumoral Dendritic Cell Administration
Cancer Res., December 1, 2003; 63(23): 8466 - 8475.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu
Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules
J. Immunol., May 15, 2003; 170(10): 5317 - 5325.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Schlienger, C. S. Chu, E. Y. Woo, P. M. Rivers, A. J. Toll, B. Hudson, M. V. Maus, J. L. Riley, Y. Choi, G. Coukos, et al.
TRANCE- and CD40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients
Clin. Cancer Res., April 1, 2003; 9(4): 1517 - 1527.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Gong, S. Koido, D. Chen, Y. Tanaka, L. Huang, D. Avigan, K. Anderson, T. Ohno, and D. Kufe
Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12
Blood, April 1, 2002; 99(7): 2512 - 2517.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. E. Strome, S. Voss, R. Wilcox, T. L. Wakefield, K. Tamada, D. Flies, A. Chapoval, J. Lu, J. L. Kasperbauer, D. Padley, et al.
Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response
Cancer Res., March 1, 2002; 62(6): 1884 - 1889.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. W. Ju, Q. Tao, G. Lou, M. Bai, L. He, Y. Yang, and X. Cao
Interleukin 18 Transfection Enhances Antitumor Immunity Induced by Dendritic Cell-Tumor Cell Conjugates
Cancer Res., May 1, 2001; 61(9): 3735 - 3740.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
K. A. Candido, K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mulé
Local Administration of Dendritic Cells Inhibits Established Breast Tumor Growth: Implications for Apoptosis-inducing Agents
Cancer Res., January 1, 2001; 61(1): 228 - 236.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.